Therefore, it is interesting to determine whether the expression of CRBN in myeloma cells is also regulated by ROS signaling, and whether the activation of the Nrf2 pathway can upregulate CRBN expression in CRBN− myeloma cells to recapture the sensitivity of IMiDs. The gene discussed is NFE2L2; the disease is plasma cell myeloma.